Log in
Selective COX-2 inhibitor (NSAID)

Celecoxib

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for osteoarthritis, rheumatoid arthritis, and acute pain. Unlike traditional NSAIDs, it was designed to spare COX-1, reducing gastrointestinal toxicity. The most testable fact is its association with increased cardiovascular risk, particularly at high doses.

Practice questionsHigh-yield facts
Drug classSelective COX-2 inhibitor (NSAID)
MechanismSelectively inhibits COX-2, reducing prostaglandin synthesis
Main usesOsteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain
Key adverse effectIncreased cardiovascular thrombotic events (MI, stroke)
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase that is upregulated at sites of inflammation. By blocking COX-2, celecoxib reduces the conversion of arachidonic acid to prostaglandin H2, thereby decreasing the production of pro-inflammatory prostaglandins such as PGE2 and PGI2.

The key distinction from traditional NSAIDs is its relative sparing of COX-1, the constitutive isoform responsible for producing prostaglandins that protect the gastric mucosa, maintain renal blood flow, and support platelet function. Celecoxib's selectivity for COX-2 over COX-1 is approximately 10- to 20-fold at therapeutic doses.

However, this selectivity is dose-dependent and decreases at higher doses. COX-2 is also expressed constitutively in some tissues, including the kidneys and vascular endothelium, explaining why COX-2 inhibitors still carry renal and cardiovascular risks despite their selectivity.

High-yield for exams
  • Celecoxib selectively inhibits COX-2, sparing COX-1 and reducing GI toxicity compared to traditional NSAIDs.
  • Black box warning: increased risk of MI, stroke, and serious GI events (bleeding, ulceration, perforation).
  • Contraindicated in aspirin triad (asthma, nasal polyps, aspirin hypersensitivity) and perioperative CABG surgery.
  • Metabolized by CYP2C9; poor metabolizers have increased drug levels and toxicity risk.
  • Does not inhibit platelet function, unlike traditional NSAIDs, so no cardioprotective effect.
  • Avoid in third trimester of pregnancy (risk of premature ductus arteriosus closure).
  • Triple whammy: NSAID + ACE inhibitor/ARB + diuretic increases acute kidney injury risk.
  • Sulfonamide derivative; use cautiously in patients with sulfonamide allergy.

Indications

Celecoxib is FDA-approved for the following conditions:

  • Osteoarthritis: relief of signs and symptoms
  • Rheumatoid arthritis: relief of signs and symptoms in adults
  • Ankylosing spondylitis: relief of signs and symptoms
  • Acute pain: short-term management in adults
  • Primary dysmenorrhea: management of menstrual pain
  • Juvenile rheumatoid arthritis (JRA): in patients aged 2 years and older

Celecoxib is also used off-label for various painful conditions and inflammatory disorders. It was previously approved for familial adenomatous polyposis (FAP) to reduce adenomatous colorectal polyps, but this indication is no longer routinely recommended due to cardiovascular concerns.

The drug is generally reserved for patients who require chronic NSAID therapy but are at elevated risk for gastrointestinal complications, or when traditional NSAIDs are not tolerated.

Pharmacokinetics

Absorption: Celecoxib is well absorbed after oral administration, with peak plasma concentrations reached in approximately 3 hours. Food, especially high-fat meals, can increase absorption.

Distribution: The drug is highly protein-bound (approximately 97%, primarily to albumin). It has a volume of distribution of approximately 400 L.

Metabolism: Celecoxib is extensively metabolized in the liver primarily by cytochrome P450 2C9 (CYP2C9) to inactive metabolites. Patients with CYP2C9 polymorphisms (poor metabolizers) may have significantly elevated plasma concentrations and increased risk of adverse effects.

Elimination: The elimination half-life is approximately 11 hours. Metabolites are excreted primarily in feces (57%) and urine (27%). Negligible amounts of unchanged drug are found in urine.

Special populations: Elderly patients and those with hepatic impairment may have increased drug exposure. Dosage reduction is recommended in patients with moderate hepatic impairment (Child-Pugh Class B). Celecoxib is not recommended in severe hepatic impairment.

Adverse effects

Cardiovascular

Black Box Warning: Celecoxib increases the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk may increase with duration of use and in patients with cardiovascular disease or risk factors. The mechanism involves selective inhibition of COX-2-derived prostacyclin (PGI2) in vascular endothelium while leaving platelet COX-1-derived thromboxane A2 unopposed, creating a prothrombotic state.

Other cardiovascular effects include hypertension, edema, and exacerbation of heart failure.

Gastrointestinal

Black Box Warning: NSAIDs, including celecoxib, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.

While celecoxib has lower GI toxicity than traditional NSAIDs, the risk is not eliminated. Common GI effects include dyspepsia, abdominal pain, diarrhea, and nausea.

Renal

COX-2 inhibitors can cause fluid retention, edema, hyperkalemia, and acute renal failure. They may precipitate renal decompensation in patients with pre-existing renal impairment, heart failure, or volume depletion. Long-term use may lead to renal papillary necrosis and chronic kidney disease.

Hepatic

Elevations in liver enzymes (ALT, AST) occur in approximately 1-3% of patients. Rare cases of severe hepatotoxicity, including fulminant hepatitis, hepatic necrosis, and hepatic failure (sometimes fatal), have been reported.

Hypersensitivity

Serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Anaphylaxis and angioedema may occur, particularly in patients with aspirin-sensitive asthma.

Other

  • Dizziness, headache
  • Increased risk of bleeding (though less than traditional NSAIDs)
  • Exacerbation of asthma in aspirin-sensitive patients
  • Possible impairment of female fertility (reversible upon discontinuation)

Contraindications and warnings

Absolute contraindications:

  • Known hypersensitivity to celecoxib, sulfonamides, aspirin, or other NSAIDs
  • History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs (aspirin triad: asthma, nasal polyps, aspirin sensitivity)
  • Use in the setting of coronary artery bypass graft (CABG) surgery (contraindicated perioperatively)
  • Third trimester of pregnancy

Warnings and precautions:

  • Cardiovascular disease: Use with caution in patients with known cardiovascular disease or risk factors. Use the lowest effective dose for the shortest duration.
  • Gastrointestinal disease: History of peptic ulcer disease or GI bleeding increases risk. Consider concomitant proton pump inhibitor therapy in high-risk patients.
  • Renal impairment: Use cautiously; monitor renal function, especially in elderly patients, those with heart failure, or volume depletion.
  • Hepatic impairment: Contraindicated in severe impairment; reduce dose by 50% in moderate impairment.
  • Hypertension: NSAIDs can blunt the effects of antihypertensive medications; monitor blood pressure.
  • Heart failure: COX-2 inhibitors can cause fluid retention and exacerbate heart failure.
  • Pregnancy: Avoid use, particularly after 30 weeks gestation (risk of premature closure of fetal ductus arteriosus and oligohydramnios).
  • CYP2C9 poor metabolizers: Consider starting at half the recommended dose.
  • Concurrent anticoagulation: Increases bleeding risk when used with warfarin, DOACs, or antiplatelet agents.

Drug interactions

CYP2C9 inhibitors: Fluconazole and other CYP2C9 inhibitors can increase celecoxib plasma concentrations, increasing the risk of toxicity. Consider dose reduction.

Anticoagulants and antiplatelets: Celecoxib increases bleeding risk when combined with warfarin, heparin, direct oral anticoagulants (DOACs), aspirin, or other antiplatelet agents. Monitor closely and consider GI prophylaxis.

Aspirin: Concomitant use increases the risk of GI ulceration and bleeding. Low-dose aspirin for cardiovascular prophylaxis does not mitigate the cardiovascular risk of celecoxib.

ACE inhibitors, ARBs, and diuretics: NSAIDs may reduce the antihypertensive effects of these medications and increase the risk of renal impairment, particularly in volume-depleted patients. The combination of an NSAID, ACE inhibitor/ARB, and diuretic is sometimes called the "triple whammy" for acute kidney injury risk.

Lithium: Celecoxib may increase lithium plasma concentrations by reducing renal clearance, potentially leading to lithium toxicity. Monitor lithium levels.

Methotrexate: NSAIDs may decrease methotrexate clearance, increasing the risk of methotrexate toxicity, particularly at higher doses.

SSRIs and SNRIs: Concurrent use may increase the risk of GI bleeding.

Corticosteroids: Combination increases the risk of GI ulceration and bleeding.

Clinical pearls

  • Celecoxib is a sulfonamide derivative and should be used cautiously in patients with sulfonamide allergy, though true cross-reactivity is debated.
  • The PRECISION trial (2016) demonstrated that celecoxib had non-inferior cardiovascular safety compared to naproxen and ibuprofen at moderate doses, challenging earlier concerns from the withdrawn rofecoxib (Vioxx).
  • Despite COX-1 sparing, celecoxib does not provide cardioprotection like aspirin because it does not irreversibly inhibit platelet COX-1.
  • The GI benefit of celecoxib over traditional NSAIDs is most pronounced in patients not taking concurrent low-dose aspirin. Aspirin co-administration negates much of the GI advantage.
  • Celecoxib has no effect on platelet function at standard doses, unlike traditional NSAIDs. This makes it useful in patients with bleeding risk but also means it should not be used when antiplatelet effects are desired.
  • Consider CYP2C9 genotype in patients with unexpectedly high drug levels or toxicity; poor metabolizers may require dose adjustment.
  • For patients requiring chronic NSAID therapy with cardiovascular risk factors, naproxen may be preferred due to its more favorable cardiovascular profile, despite higher GI toxicity.
  • The capsule formulation contains lactose; consider this in lactose-intolerant patients.
  • Discontinue celecoxib if liver enzymes exceed three times the upper limit of normal.
  • In aspirin-exacerbated respiratory disease (AERD), celecoxib is generally considered safer than traditional NSAIDs but is not completely without risk.

Practice questions

1. A 62-year-old man with a history of myocardial infarction 6 months ago presents with worsening knee pain due to osteoarthritis. He has tried acetaminophen without adequate relief. His current medications include aspirin, atorvastatin, and metoprolol. Which of the following is the most appropriate next step in management?

Answer: D. This patient has recent MI and is at high cardiovascular risk. All NSAIDs, including celecoxib, increase the risk of cardiovascular thrombotic events and should be avoided if possible in patients with recent MI or established coronary artery disease. Intra-articular corticosteroid injection provides local pain relief without systemic cardiovascular risk. If an NSAID were necessary, naproxen has the most favorable cardiovascular profile, but avoidance is preferred. Tramadol is an option but has its own risks (seizures, dependency).

2. A 58-year-old woman with rheumatoid arthritis has been taking celecoxib for 3 months with good symptom control. She develops peripheral edema and her blood pressure, previously well-controlled on lisinopril, increases from 128/78 to 148/92 mm Hg. Laboratory studies show creatinine increased from 0.9 to 1.4 mg/dL. Which of the following best explains these findings?

Answer: C. This patient demonstrates the classic renal effects of NSAIDs including COX-2 inhibitors. Prostaglandins, particularly PGE2 and PGI2, maintain renal blood flow by causing afferent arteriolar vasodilation. COX-2 inhibition reduces these protective prostaglandins, leading to decreased renal perfusion, sodium and water retention (causing edema and hypertension), and potential acute kidney injury. The combination of an NSAID with an ACE inhibitor further compromises renal hemodynamics. This is not hypersensitivity or direct ACE inhibitor toxicity.

3. A 45-year-old woman presents to the emergency department with acute urticaria, wheezing, and facial swelling 30 minutes after taking her first dose of celecoxib for knee pain. She has a history of asthma that worsens when she takes aspirin or ibuprofen, and she has nasal polyps. What is the underlying mechanism of her reaction?

Answer: B. This patient has aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad (asthma, nasal polyps, aspirin sensitivity). The mechanism involves COX-1 inhibition shunting arachidonic acid metabolism toward the lipoxygenase pathway, increasing production of cysteinyl leukotrienes that cause bronchoconstriction and inflammation. While celecoxib is COX-2 selective, it can still inhibit COX-1 at therapeutic doses or in susceptible individuals. This is a pharmacologic pseudo-allergic reaction, not a true IgE-mediated allergy, though the clinical presentation is similar.

Frequently asked questions

How does celecoxib work?

Celecoxib selectively inhibits the COX-2 enzyme, which is responsible for producing inflammatory prostaglandins at sites of tissue injury and inflammation. By blocking COX-2 while largely sparing COX-1 (the enzyme that protects the stomach lining and supports platelet function), celecoxib reduces pain and inflammation with theoretically lower gastrointestinal side effects than traditional NSAIDs. However, this selectivity also contributes to its cardiovascular risks.

What are the side effects of celecoxib?

The most serious side effects include increased risk of heart attack, stroke, gastrointestinal bleeding, ulceration, and kidney problems. Common side effects include stomach pain, diarrhea, indigestion, headache, and swelling in the legs or feet. Rare but serious reactions include severe skin reactions, liver toxicity, and allergic reactions. Patients with cardiovascular disease, kidney disease, or a history of stomach ulcers are at higher risk for complications.

Is celecoxib safer than ibuprofen?

Celecoxib causes less gastrointestinal toxicity (ulcers and bleeding) than ibuprofen in patients not taking aspirin, but both carry similar cardiovascular risks at therapeutic doses according to the PRECISION trial. Celecoxib does not affect platelet function, so it may be preferred in patients at risk for bleeding. However, ibuprofen and naproxen are generally less expensive. The choice depends on individual patient risk factors, cost considerations, and whether GI or cardiovascular risk predominates.

Can I take celecoxib if I am allergic to sulfa drugs?

Celecoxib contains a sulfonamide (SO2NH2) moiety, raising theoretical concerns in patients with sulfonamide antibiotic allergies. However, most allergic reactions to sulfonamide antibiotics are caused by a different part of the molecule (the arylamine group) not present in celecoxib. Cross-reactivity is rare but possible. If you have a history of severe sulfonamide allergy (such as Stevens-Johnson syndrome), celecoxib should be avoided. For mild reactions, it may be used cautiously under medical supervision.

Why was Vioxx recalled but celecoxib was not?

Rofecoxib (Vioxx) was withdrawn in 2004 due to significantly increased cardiovascular risk, particularly heart attacks and strokes, observed in clinical trials. While celecoxib also carries cardiovascular risks as a COX-2 inhibitor, subsequent studies including the PRECISION trial showed its cardiovascular safety profile is similar to traditional NSAIDs like ibuprofen and naproxen at moderate doses. Rofecoxib had greater COX-2 selectivity and longer half-life, which may have contributed to its higher risk profile compared to celecoxib.

Conditions it is used for

OsteoarthritisRheumatoid arthritisAnkylosing spondylitisAcute painPrimary dysmenorrheaJuvenile idiopathic arthritis
IbuprofenNaproxenDiclofenacMeloxicamIndomethacinKetorolacEtoricoxibRofecoxib

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: L01XX33WHO ATC/DDD index: M01AH01

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.